Clinical Trial Update: Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating nintedanib in combination with docetaxel as second-line therapy for lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Neoplasms

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Nintedanib (nintedanib)

Snippet

Sponsor: University Hospital, Limoges | Conditions: Lung Neoplasms | Phase 2 | Status: COMPLETED